Kovaks-19
Appearance
Klinički podaci | |
---|---|
Prodajno ime | Spikogen[1] |
Način primene | u mišić |
Pravni status | |
Pravni status |
|
Kovaks-19 (COVAX-19 ili SpikoGen) je rekombinantna vakcina protiv kovida 19 zasnovana na proteinima koju je razvila biotehnološka kompanija Vaxine iz Južne Australije. U toku je kliničko ispitivanje vakcine u saradnji sa iranskom kompanijom CinnaGen.[2][3][4]
Klinička ispitivanja
[uredi | uredi izvor]Faza | Registracioni broj | Početak | Broj ispitanika | Starost ispitanika | Lokacija | Izvori | ||
---|---|---|---|---|---|---|---|---|
Ukupno | Vakcina | Placebo | ||||||
I | NCT04453852 | 30. jun 2020 | 40 | 30 | 10 | 18–65 godina | Adelaide, Australija | [5][6] |
II | IRCT20150303021315N23 Arhivirano na sajtu Wayback Machine (11. jul 2021) | 30. maj 2021 | 400 | 300 | 100 | 18+ godina | Teheran, Iran | [7] |
NCT04944368 | [8] | |||||||
III | IRCT20150303021315N24 | 7. avgust 2021 | 16,876 | 12,657 | 4,219 | 18–50 godina | Teheran, Iran | [3] |
NCT05005559 | [9] |
Izvori
[uredi | uredi izvor]- ^ Clinical Trials NCT04944368 Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
- ^ „"Spikogen", A Joint Venture Between Vaxine And Cinnagen”. Vaxine. Arhivirano iz originala 11. 07. 2021. g. Pristupljeno 24. 01. 2022.
- ^ a b „A phase III, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)”. irct.ir. 2. 8. 2021. IRCT20150303021315N24. Pristupljeno 3. 8. 2021.
- ^ Griffin P (23. 6. 2021). „What is COVAX-19? Australia's most advanced COVID vaccine candidate”. medicine.uq.edu.au (na jeziku: engleski). Pristupljeno 5. 8. 2021.
- ^ Vaxine Pty Ltd (5. 5. 2021). „A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects”. Central Adelaide Local Health Network Incorporated.
- ^ „چرا واکسن اسپایکوژن؟ | واکسن کرونا اسپایکوژن | spikogen” (na jeziku: persijski). 26. 4. 2020. Arhivirano iz originala 09. 07. 2021. g. Pristupljeno 7. 9. 2021.
- ^ „IRCT | A phase II, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)”. en.irct.ir. Arhivirano iz originala 11. 07. 2021. g. Pristupljeno 7. 9. 2021.
- ^ Cinnagen (14. 8. 2021). „A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)”. Vaxine Pty Ltd.
- ^ Cinnagen (11. 8. 2021). „A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)”. Vaxine Pty Ltd.
Spoljašnje veze
[uredi | uredi izvor]![]() | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |